Sign inJoin waitlistJoin the waitlist

Patricia LoRusso

Chief, Experimental Therapeutics · Yale School of Medicine

Credentials: · · · · · · ·

History

Experimental Therapeutics Division · Yale School of Medicine
Present
Experimental Therapeutics Division · Yale School of Medicine
Present
Yale School of Medicine
Present

Wayne State University
Until 1988
Riverside Osteopathic Hospital
Until 1984
Riverside Osteopathic Hospital
Until 1982
Michigan State University
1981
Marygrove College
1977

Research

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
The Lancet Oncology · 2012 · 1,019 citations
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
New England Journal of Medicine · 2009 · 873 citations
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile
Science Translational Medicine · 2012 · 823 citations

Geoffrey Shapiro
25 papers
EH
Elisabeth Heath
19 papers
HB
Howard Burris
19 papers
AT
Anthony Tolcher
18 papers
JE
Joseph Eder
18 papers
David Hong
15 papers
AS
Anthony Shields
14 papers
JI
Jeffrey Infante
13 papers
Razelle Kurzrock
13 papers
Aung Naing
12 papers
IK
Ian Krop
12 papers
Shirish Gadgeel
12 papers

Grants

Multiplexed Spatially Resolved Tissue Biomarkers for Optimal Use of PD-1 Axis Blockers and PARP Inhibitors in Cancer.
National Cancer Institute · UH2
PI · $461.4K · Yale University
2025–2027
Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials Consortium
National Cancer Institute · UM1
Contact PI · $22.2M · Yale University
2014–2027
Early Clinical Trials of New Anti-Cancer Agents
National Cancer Institute · U01
Contact PI · $9.5M · Wayne State University
1994–2015
Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU
National Cancer Institute · R21
Contact PI · $668.8K · Wayne State University
2009–2014

Clinical trials

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2027
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
Principal investigator · Withdrawn · Phase 1
National Cancer Institute (NCI)
2020
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2020–2027
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2019–2027